BioSpace News Archive

Mosaic Diagnostics is pleased to announce the appointment of Rob Rebak as Chief Executive Officer.

BIOXYTRAN, INC., a clinical stage biotechnology company developing drugs to treat stroke and Alzheimer’s disease, announced that Bioxtran’s Science Advisor Prof. Avraham Mayevsky’s book titled Hyperbaric Oxygenation Mitochondrial Activity and Brain Physiological Functions was published by a publishing house, Springer.

Chroma Medicine, Inc. (Chroma) a genomic medicine company pioneering single-course epigenetic editing therapeutics, today announced it has entered into an exclusive license agreement with the Whitehead Institute to access intellectual property and technology developed in the lab of Chroma co-founder Jonathan Weissman, Ph.D.

Bioretec Ltd., a pioneer in bioresorbable orthopedic implants, announces that according to the information received from the Notified Body, its European CE mark market authorization application for the RemeOs™ trauma screw has returned from the expert panel evaluation.

Eliem Therapeutics, Inc. (Nasdaq: ELYM) (“Eliem”), today announced the closing of its acquisition with Tenet Medicines (“Tenet”).

Azitra, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 30 pre-split shares.

Calidi Biotherapeutics, Inc. today announced the appointment of Dr. George E. Peoples, MD, FACS, to the company’s Board of Directors, effective July 1, 2024.

Jacobs was selected by FUJIFILM Diosynth Biotechnologies to support delivery of $1.2 billion expansion of an end-to-end, large-scale cell culture contract manufacturing site in Holly Springs, North Carolina.

Daré Bioscience, Inc., a leader in innovation for the health and wellbeing of women, announced that it will implement a 1-for-12 reverse split of the issued shares of its common stock, effective at 12:01 a.m. Eastern Time on July 1, 2024.

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announces that it will expand its ongoing Netherton Syndrome clinical studies to include international sites.